ABSTRACT
Using fluorescent antibody staining, we have established the association of methionyl-tRNA synthetase with the endoplasmic reticulum in PtK2 cells. After Triton X-100 extraction, 70% of the recovered aminoacyl-tRNA synthetase activity was found in the detergent-insoluble fraction. This fraction of the enzyme remained localized with insoluble endoplasmic reticulum antigens and with ribosomes, which were stained with acridine orange. By both fluorescence microscopy and electron microscopy the organization of the detergent-insoluble residue was found to depend on the composition of the extracting solution. After extraction with a microtubule-stabilizing buffer containing EGTA, Triton X-100, and polyethylene glycol (Osburn, M., and K. Weber, 1977, Cell, 12:561-571) the ribosomes were aggregated in large clusters with remnants of membranes. After extraction with a buffer containing Triton X-100, sucrose, and CaCl2 (Fulton, A. B., K. M. Wang, and S. Penman, 1980, Cell, 20:849-857), the ribosomes were in small clusters and there were few morphologically recognizable membranes. In both cases the methionyl-tRNA synthetase and some endoplasmic reticulum antigens retained approximately their normal distribution in the cell. Double fluorochrome staining showed no morphological association of methionyl-tRNA synthetase with the microtubule, actin, or cytokeratin fiber systems of PtK2 cells. These observations demonstrate that detergent-insoluble cellular components, sometimes referred to as "cytoskeletal" preparations, contain significant amounts of nonfilamentous material including ribosomes, and membrane residue. Caution is required in speculating about intermolecular associations in such a complex cell fraction.
Subject(s)
Amino Acyl-tRNA Synthetases/analysis , Endoplasmic Reticulum/enzymology , Methionine-tRNA Ligase/analysis , Animals , Cells, Cultured , Cytoskeleton/enzymology , Fluorescent Antibody Technique , Microtubules/enzymology , Polyethylene Glycols/pharmacologyABSTRACT
Fibrinogen fragment D, which is heterogeneous, has several important biological functions. Human fibrinogen fragments D94 (molecular weight, 94,000), D78 (78,000), and E (52,000) were purified. Fragments D78 and D94 but not purified fibrinogen or fragment E specifically caused disorganization of bovine aortic endothelial cells cultured as monolayers. Within 2 hours of exposure to pathophysiological concentrations of fragment D, the confluent endothelial cells retracted from each other and projected pseudopodia. These disturbed cells subsequently became rounded and detached from the substrate. The actin present in stress fibers in stationary monolayer cells was diffusely redistributed in cells with fragment D-induced alterations in morphology. This effect was not observed in monolayers of kidney epithelial cells. The results demonstrate a specific effect of fibrinogen fragment D on the disorganization of cultured vascular endothelial cell monolayers and suggest that fragment D plays a role in the pathogenesis of syndromes with vascular endothelial damage.
Subject(s)
Endothelium/cytology , Fibrin Fibrinogen Degradation Products/pharmacology , Actins/analysis , Animals , Aorta , Cattle , Cell Adhesion/drug effects , Cell Line , Cells, Cultured , Cytoskeleton/drug effects , Endothelium/analysis , Endothelium/drug effects , Endothelium/ultrastructure , Epithelial Cells , Humans , Kidney , Pseudopodia/drug effectsABSTRACT
An amino-terminal transactivation domain is required for Myc to function as a transcription factor controlling cell proliferation, differentiation, and apoptosis. A complementary DNA expression library was screened with a Myc fusion protein to identify proteins interacting with this domain, and a clone encoding the Rb-related p107 protein was isolated. The p107 protein was shown to associate with Myc in vivo and to suppress the activity of the Myc transactivation domain. However, mutant forms of Myc from Burkitt lymphoma cells, which contain sequence alterations in the transactivation domain, were resistant to p107-mediated suppression. Thus, disruption of a regulatory interaction between Myc and p107 may be important in tumorigenesis.
Subject(s)
Nuclear Proteins , Proteins/metabolism , Proto-Oncogene Proteins c-myc/metabolism , Suppression, Genetic , Transcription Factors , Transcriptional Activation , 3T3 Cells , Animals , Base Sequence , Basic Helix-Loop-Helix Leucine Zipper Transcription Factors , Basic-Leucine Zipper Transcription Factors , DNA-Binding Proteins/metabolism , Helix-Loop-Helix Motifs , Lymphoma, B-Cell , Mice , Molecular Sequence Data , Point Mutation , Proto-Oncogene Proteins c-myc/genetics , Recombinant Fusion Proteins/metabolism , Retinoblastoma-Like Protein p107 , Transfection , Tumor Cells, CulturedABSTRACT
Over seven decades ago, classical biochemical studies showed that tumors have altered metabolic profiles and display high rates of glucose uptake and glycolysis. Although these metabolic changes are not the fundamental defects that cause cancer, they might confer a common advantage on many different types of cancers, which allows the cells to survive and invade. Recent molecular studies have revealed that several of the multiple genetic alterations that cause tumor development directly affect glycolysis, the cellular response to hypoxia and the ability of tumor cells to recruit new blood vessels.
Subject(s)
Neoplasms/metabolism , Animals , Apoptosis , Endothelial Growth Factors/genetics , Gene Expression Regulation, Neoplastic , Genes, Tumor Suppressor , Glycolysis/genetics , Humans , Hypoxia/genetics , Hypoxia/metabolism , Hypoxia/pathology , Lymphokines/genetics , Neoplasms/genetics , Neoplasms/pathology , Oncogenes , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth FactorsABSTRACT
The adenomatous polyposis coli (APC) tumor suppressor protein is inactivated by mutations in the majority of colorectal cancers. A recent study has revealed that alterations in the APC signaling pathway can result in the transcriptional activation of the c-MYC gene.
Subject(s)
Genes, APC , Oncogenes , Genes, myc , Humans , Mutation , Signal Transduction , Transcriptional ActivationABSTRACT
Deregulated expression of the c-Myc oncoprotein occurs in several human malignancies. The c-Myc protein behaves as a transcription factor, and undoubtedly its role in carcinogenesis involves its ability to affect the expression of genes involved in cell growth. c-Myc has been reported to both activate and repress transcription in transient transfection experiments using reporter constructs bearing multiple copies of the c-Myc binding site, CAC (G/A) TG. We investigated these apparently paradoxical effects of c-Myc by determining if they arose from differences in the cell proliferation states of transfected cells. We found that endogenous c-Myc protein levels vary inversely with the degree of cell confluency, such that at low cell confluency, where endogenous levels of c-Myc are high and presumably endogenous levels of Max are limiting, exogenous c-Myc fails to affect basal transcription. In cells at high cell confluency, in which endogenous c-Myc levels are low, exogenous c-Myc augments transactivation by titrating the relative excess endogenous Max. These observations suggest that the apparently paradoxical behavior of c-Myc in transfection experiments is partially dependent on ambient cellular levels of c-Myc.
Subject(s)
DNA-Binding Proteins/metabolism , Proto-Oncogene Proteins c-myc/metabolism , Transcription Factors/metabolism , Transcription, Genetic , Animals , Base Sequence , Basic Helix-Loop-Helix Leucine Zipper Transcription Factors , Basic-Leucine Zipper Transcription Factors , Binding Sites , Fibroblasts/cytology , Fibroblasts/metabolism , Helix-Loop-Helix Motifs , Humans , Kinetics , L Cells , Mice , Molecular Sequence Data , Plasmids , Transcriptional Activation , TransfectionABSTRACT
Recent studies indicate that the transcription factor c-Myc contributes to oncogenesis by altering the expression of genes involved in cell proliferation, but its precise function in neoplasia remains ambiguous. The ability of c-Myc to bind the sequence CAC(G/A)TG and transactivate appears to be linked to its transforming activity; however, c-Myc also represses transcription in vitro through a pyrimidine-rich cis element termed the initiator (Inr). In transfection experiments using the adenoviral major late (adML) promoter, which contains two Myc binding sites and an Inr, we determined that c-Myc represses transcription through the initiator in vivo. This activity requires the dimerization domain and amino acids 106 to 143, which are located within the transactivation domain and are necessary for neoplastic transformation. We studied a lymphoma-derived c-Myc substitution mutation at 115-Phe, which is within the region required for transcriptional suppression, and found the mutant more effective than wild-type c-Myc in transforming rodent fibroblasts and in suppressing the adML promoter. Our studies of both loss-of-function and gain-of-function c-Myc mutations suggest a link between c-Myc-mediated neoplastic transformation and transcriptional repression through the Inr.
Subject(s)
Cell Transformation, Neoplastic/genetics , Genes, myc , Animals , Base Sequence , Binding Sites/genetics , Cell Line , DNA Primers/genetics , Humans , L Cells , Lymphoma/genetics , Mice , Molecular Sequence Data , Mutation , Plasmids/genetics , Promoter Regions, Genetic , Rats , Transcription, Genetic , TransfectionABSTRACT
Arsenic is effective in the treatment of acute promyelocytic leukemia. Paradoxically, it is also carcinogenic. In the process of elucidating a mechanism of arsenic resistance in a leukemia cell line, NB4, we discovered that arsenic exposure causes chromosomal abnormalities, with a preponderance of end-to-end fusions. These chromosomal end fusions suggested that telomerase activity may be inhibited by arsenic. We found that arsenic inhibits transcription of the hTERT gene, which encodes the reverse transcriptase subunit of human telomerase. This effect may in part be explained by decreased c-Myc and Sp1 transcription factor activities. Decreased telomerase activity leads to chromosomal end lesions, which promote either genomic instability and carcinogenesis or cancer cell death. These phenomena may explain the seemingly paradoxical carcinogenic and antitumor effects of arsenic.
Subject(s)
Arsenic/pharmacology , Gene Expression Regulation, Enzymologic/drug effects , Telomerase/genetics , Transcription, Genetic/drug effects , 3T3 Cells , Animals , Base Sequence , Chromosomes, Human , DNA/metabolism , DNA Primers , DNA-Binding Proteins , Humans , Mice , Sp1 Transcription Factor/antagonists & inhibitors , Sp1 Transcription Factor/metabolism , Tumor Cells, CulturedABSTRACT
The c-Myc oncogenic transcription factor plays a central role in many human cancers through the regulation of gene expression. Although the molecular mechanisms by which c-Myc and its obligate partner, Max, regulate gene expression are becoming better defined, genes or transcriptomes that c-Myc regulate are just emerging from a variety of different experimental approaches. Studies of individual c-Myc target genes and their functional implications are now complemented by large surveys of c-Myc target genes through the use of subtraction cloning, DNA microarray analysis, serial analysis of gene expression (SAGE), chromatin immunoprecipitation, and genome marking methods. To fully appreciate the differences between physiological c-Myc function in normal cells and deregulated c-Myc function in tumors, the challenge now is to determine how the authenticated transcriptomes effect the various phenotypes induced by c-Myc and to define how c-Myc transcriptomes are altered by the Mad family of proteins.
Subject(s)
Proto-Oncogene Proteins c-myc/metabolism , Animals , Basic-Leucine Zipper Transcription Factors/metabolism , Cell Adhesion , Cell Cycle , Humans , Oligonucleotide Array Sequence Analysis , Protein Biosynthesis , Transcription, GeneticABSTRACT
We identified and characterized two regions of the human c-myc protein that target proteins into the nucleus. Using mutant c-myc proteins and proteins that fuse portions of c-myc to chicken muscle pyruvate kinase, we found that residues 320 to 328 (PAAKRVKLD; peptide M1) induced complete nuclear localization, and their removal from c-myc resulted in mutant proteins that distributed in both the nucleus and cytoplasm but retained rat embryo cell cotransforming activity. Residues 364 to 374 (RQRRNELKRSP; peptide M2) induced only partial nuclear targeting, and their removal from c-myc resulted in mutant proteins that remained nuclear but were cotransformationally inactive. We conjugated synthetic peptides containing M1 or M2 to human serum albumin and microinjected the conjugate into the cytoplasm of Vero cells. The peptide containing M1 caused rapid and complete nuclear accumulation, whereas that containing M2 caused slower and only partial nuclear localization. Thus, M1 functions as the nuclear localization signal of c-myc, and M2 serves some other and essential function.
Subject(s)
Nuclear Proteins/genetics , Proto-Oncogene Proteins/genetics , Amino Acid Sequence , Cell Compartmentation , Cell Transformation, Neoplastic/genetics , DNA Mutational Analysis , Fluorescent Antibody Technique , Molecular Sequence Data , Oncogenes , Proto-Oncogene Proteins/metabolism , Pyruvate Kinase/genetics , Recombinant Fusion Proteins/metabolism , Structure-Activity RelationshipABSTRACT
c-myc has been shown to regulate G(1)/S transition, but a role for c-myc in other phases of the cell cycle has not been identified. Exposure of cells to colcemid activates the mitotic spindle checkpoint and arrests cells transiently in metaphase. After prolonged colcemid exposure, the cells withdraw from mitosis and enter a G(1)-like state. In contrast to cells in G(1), colcemid-arrested cells have decreased G(1) cyclin-dependent kinase activity and show hypophosphorylation of the retinoblastoma protein. We have found that overexpression of c-myc causes colcemid-treated human and rodent cells to become either apoptotic or polyploid by replicating DNA without chromosomal segregation. Although c-myc-induced polyploidy is not inhibited by wild-type p53 in immortalized murine fibroblasts, overexpression of c-myc in primary fibroblasts resulted in massive apoptosis of colcemid-treated cells. We surmise that additional genes are altered in immortalized cells to suppress the apoptotic pathway and allow c-myc-overexpressing cells to progress forward in the presence of colcemid. Our results also suggest that c-myc induces DNA rereplication in this G(1)-like state by activating CDK2 activity. These observations indicate that activation of c-myc may contribute to the genomic instability commonly found in human cancers.
Subject(s)
Cell Cycle/genetics , DNA Replication/genetics , Gene Expression Regulation , Genes, myc , Mitosis/genetics , Proto-Oncogene Proteins c-myc/biosynthesis , Proto-Oncogene Proteins , Animals , Apoptosis/drug effects , Cell Cycle/drug effects , Cell Line, Transformed , Cyclin-Dependent Kinase 4 , Cyclin-Dependent Kinases/metabolism , DNA Replication/drug effects , Demecolcine/pharmacology , Fibroblasts/drug effects , Fibroblasts/metabolism , Genes, Retinoblastoma , Genes, p53 , Genes, ras , Humans , Mitosis/drug effects , Models, Biological , Neoplasms/genetics , Rats , Recombinant Fusion Proteins/physiology , Spindle Apparatus/drug effectsABSTRACT
We have identified the domain of the human c-myc protein (c-Myc) produced in Escherichia coli that is responsible for the ability of the protein to bind sequence-nonspecific DNA. Using analysis of binding of DNA by proteins transferred to nitrocellulose, DNA-cellulose chromatography, and a nitrocellulose filter binding assay, we examined the binding properties of c-Myc peptides generated by cyanogen bromide cleavage, of mutant c-Myc, and of proteins that fuse portions of c-Myc to staphylococcal protein A. The results of these analyses indicated that c-Myc amino acids 265 to 318 were responsible for DNA binding and that other regions of the protein (including a highly conserved basic region and a region containing the leucine zipper motif) were not required. Some mutant c-Mycs that did not bind DNA maintained rat embryo cell-cotransforming activity, which indicated that the c-Myc property of in vitro DNA binding was not essential for this activity. These mutants, however, were unable to transform established rat fibroblasts (Rat-1a cells) that were susceptible to transformation by wild-type c-Myc, although this lack of activity may not have been due to their inability to bind DNA.
Subject(s)
DNA-Binding Proteins/genetics , DNA/metabolism , Escherichia coli/genetics , Proto-Oncogene Proteins/genetics , Amino Acid Sequence , Animals , Base Sequence , Chromatography/methods , Cloning, Molecular , Cyanogen Bromide , DNA-Binding Proteins/metabolism , Humans , Immunoblotting , Molecular Sequence Data , Mutation , Precipitin Tests , Proto-Oncogene Proteins/metabolism , Proto-Oncogene Proteins c-myc , Rats , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism , Replicon , Staphylococcal Protein A/geneticsABSTRACT
The product of the c-myc proto-oncogene is a nuclear phosphoprotein whose normal cellular function has not yet been defined. c-Myc has a number of biochemical properties, however, that suggest that it may function as a potential regulator of gene transcription. Specifically, it is a nuclear DNA-binding protein with a short half-life, a high proline content, segments that are rich in glutamine and acidic residues, and a carboxyl-terminal oligomerization domain containing the leucine zipper and helix-loop-helix motifs that serve as oligomerization domains in known regulators of transcription, such as C/EBP, Jun, Fos, GCN4, MyoD, E12, and E47. In an effort to establish that c-Myc might regulate transcription in vivo, we sought to determine whether regions of the c-Myc protein could activate transcription in an in vitro system. We report here that fusion proteins in which segments of human c-Myc are linked to the DNA-binding domain of the yeast transcriptional activator GAL4 can activate transcription from a reporter gene linked to GAL4-binding sites. Three independent activation regions are located between amino acids 1 and 143, a region that has been shown to be required for neoplastic transformation of primary rat embryo cells in cooperation with a mutated ras gene. These results demonstrate that domains of the c-Myc protein can function to regulate transcription in a model system and suggest that alterations of Myc transcriptional regulatory function may lead to neoplastic transformation.
Subject(s)
Cell Transformation, Neoplastic , Proto-Oncogene Proteins c-myc/genetics , Proto-Oncogenes , Transcription, Genetic , Amino Acid Sequence , Animals , Cell Line , Chimera , Exons , Gene Expression Regulation , Molecular Sequence Data , Oligonucleotide Probes , Protein Biosynthesis , Protein-Tyrosine Kinases/metabolism , Proto-Oncogene Mas , Proto-Oncogene Proteins c-myc/metabolism , Restriction Mapping , TransfectionABSTRACT
The hepatitis B virus X gene product transactivates a variety of cellular and viral genes. The mechanism for X induction of RNA polymerase (pol) III genes was investigated. By using Drosophila S-2 cells stably transformed with the X gene, the transient expression of a tRNA gene is enhanced. Comparing the transcriptional activities of extracts derived from these cells, all three types of RNA pol III promoters are stimulated by X. Interestingly, both S-2 and rat 1A cells stably transformed with the X gene produce increased cellular levels of the TATA-binding protein (TBP). By using various kinase inhibitors, it was found that the X-mediated increases in both transcription and TBP are dependent upon protein kinase C activation. Since TBP is a subunit of TFIIIB, the activity of this component fractionated from extracts derived from control and X-transformed cells was analyzed. These studies reveal that TFIIIB activity is substantially more limiting in control cells and that TFIIIB isolated from X-transformed cells has increased activity in reconstitution assays compared with TFIIIB isolated from control cells. Conversely, comparison of TFIIIC from control and X-transformed cell extracts revealed that there is relatively little change in its ability either to reconstitute transcription or to bind to DNA and that there is no change in the catalytic activity of RNA pol III. Studies were performed to determine whether directly increasing cellular TBP alone could enhance RNA pol III gene transcription. Transient expression of a TBP cDNA in rat 1A cells was capable of stimulating transcription activity from the resultant extracts in vitro. Together, these results demonstrate that one mechanism by which X mediates transactivation of RNA poll III genes is by increasing limiting TBP via the activation of cellular signaling pathways. The discovery that X increases cellular TBP, the universal transcription factor, provides a novel mechanism for the function of a viral transactivator protein and may explain the ability of X to produce such large and diverse effects on cellular gene expression.
Subject(s)
DNA-Binding Proteins/metabolism , RNA Polymerase III/genetics , Trans-Activators/metabolism , Transcription Factors/metabolism , Transcriptional Activation , Animals , Base Sequence , Cell Line , Cell Line, Transformed , Copper/pharmacology , Copper Sulfate , DNA Primers , DNA-Binding Proteins/biosynthesis , Drosophila melanogaster , Kinetics , Molecular Sequence Data , Plasmids , Polymerase Chain Reaction , Protein Kinases/metabolism , Rats , Recombinant Proteins/biosynthesis , Recombinant Proteins/metabolism , TATA Box , TATA-Box Binding Protein , Trans-Activators/biosynthesis , Transcription Factors/biosynthesis , Transcription, Genetic , Viral Regulatory and Accessory ProteinsABSTRACT
Current models predict that beta-catenin (beta-cat) functions in Wnt signaling via activation of Tcf/Lef target genes and that its abundance is regulated by the adenomatous polyposis coli (APC) and glycogen synthase kinase 3beta (GSK3beta) proteins. In colon and other cancers, mutations in APC or presumptive GSK3beta phosphorylation sites of beta-cat are associated with constitutive activation of Tcf/Lef transcription. In spite of assumptions about its oncogenic potential, prior efforts to demonstrate that mutated beta-cat will induce neoplastic transformation have yielded equivocal results. We report here that mutated, but not wild-type, beta-cat proteins induced neoplastic transformation of RK3E, an adenovirus E1A-immortalized epithelial cell line. Analysis of the properties of mutant beta-cat proteins and studies with a dominant negative Tcf-4 mutant indicated that the ability of beta-cat to bind and activate Tcf/Lef factors is crucial for transformation. c-myc has recently been implicated as a critical Tcf-regulated target gene. However, c-myc was not consistently activated in beta-cat-transformed RK3E cells, and a dominant negative c-Myc mutant protein failed to inhibit beta-cat transformation. Our findings underscore the role of beta-cat mutations and Tcf/Lef activation in cancer and illustrate a useful system for defining critical factors in beta-cat transformation.
Subject(s)
Cell Transformation, Neoplastic/genetics , Cytoskeletal Proteins/genetics , DNA-Binding Proteins/genetics , Gene Expression Regulation , Genes, myc , Trans-Activators , Transcription Factors/genetics , Transcription, Genetic , Zebrafish Proteins , Adenoviridae/physiology , Animals , Calcium-Calmodulin-Dependent Protein Kinases/genetics , Cell Line, Transformed/metabolism , Cell Transformation, Viral , Cytoskeletal Proteins/physiology , Epithelial Cells , Genes, APC , Glycogen Synthase Kinase 3 , Glycogen Synthase Kinases , Kidney , Lymphoid Enhancer-Binding Factor 1 , Mutagenesis, Site-Directed , Proto-Oncogene Proteins/physiology , Rats , Signal Transduction , Wnt Proteins , beta CateninABSTRACT
B-myc is a recently described myc gene whose product has not been functionally characterized. The predicted product of B-myc is a 168-amino-acid protein with extensive homology to the c-Myc amino-terminal region, previously shown to contain a transcriptional activation domain. We hypothesized that B-Myc might also function in transcriptional regulation, although its role in regulating gene expression is predicted to be unique, because B-Myc lacks the specific DNA-binding motif found in other Myc proteins. To determine whether B-Myc could interact with the transcriptional machinery, we studied the transcriptional activation properties of a chimeric protein containing B-Myc sequences fused to the DNA-binding domain of the yeast transcriptional activator GAL4 (GAL4-B-Myc). We found that GAL4-B-Myc strongly activated expression of a GAL4-regulated reporter gene in mammalian cells. In addition, full-length B-Myc was able to inhibit or squelch reporter gene activation by a GAL4 chimeric protein containing the c-Myc transcriptional activation domain. We also observed that B-Myc dramatically inhibited the neoplastic cotransforming activity of c-Myc and activated Ras in rat embryo cells. Because B-Myc inhibits both neoplastic transformation and transcriptional activation by c-Myc, we suggest that the transforming activity of c-Myc is related to its ability to regulate transcription. Whether B-Myc functions biologically to squelch transcription and/or to regulate transcription through a specific DNA-binding protein remains unestablished.
Subject(s)
Cell Transformation, Neoplastic/genetics , Proto-Oncogene Proteins c-myc/genetics , Saccharomyces cerevisiae Proteins , Transcription Factors , Transcription, Genetic , Animals , Base Sequence , Binding, Competitive , CHO Cells , Cells, Cultured , Cricetinae , DNA , DNA-Binding Proteins , Fungal Proteins/genetics , Fungal Proteins/metabolism , Gene Expression Regulation , Molecular Sequence Data , Rats , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism , Transcriptional ActivationABSTRACT
Previous studies have documented that 250 bp of the rat cardiac ventricular myosin light-chain 2 (MLC-2v) promoter is sufficient to confer cardiac muscle-specific expression on a luciferase reporter gene in both transgenic mice and primary cultured neonatal rat myocardial cells. Utilizing ligation-mediated PCR to perform in vivo dimethyl sulfate footprinting, the present study has identified protein-DNA interaction within the position from -176 to -165. This region, identified as MLE1, contains a core sequence, CACGTG, which conforms to the consensus E-box site and is identical to the upstream stimulating factor (USF)-binding site of the adenovirus major late promoter. Transient assays of luciferase reporter genes containing point mutations of the site demonstrate the importance of this cis regulatory element in the transcriptional activation of this cardiac muscle gene in ventricular muscle cells. The protein complex that occupies this site is capable of binding to HF-1a and PRE B sites which are known to be required for cardiac muscle-specific expression of rat MLC-2v and alpha-myosin heavy-chain genes, respectively. This study provides direct evidence that USF, a member of the basic helix-loop-helix leucine zipper family, binds to MLE1, HF-1a, and PRE B sites and suggests that it is a component of protein complexes that may coordinately control the expression of MLC-2v and alpha-myosin heavy-chain genes. The current study also provides evidence that USF can positively and negatively regulate the MLC-2v gene via independent cis regulatory elements.
Subject(s)
DNA-Binding Proteins/metabolism , Genes, Regulator , Helix-Loop-Helix Motifs/genetics , Myocardium/metabolism , Myosins/genetics , Transcription Factors/metabolism , Animals , Base Sequence , Binding Sites , Cell Nucleus/metabolism , Cells, Cultured , DNA/genetics , DNA/metabolism , DNA-Binding Proteins/genetics , Gene Expression Regulation , Mice , Mice, Transgenic , Molecular Sequence Data , Promoter Regions, Genetic , Rats , Transcription Factors/genetics , Upstream Stimulatory FactorsABSTRACT
The ability of a transcription factor to function in vivo must be determined in part by its ability to bind to its recognition site in chromatin. We have used Max and derivatives of c-Myc to characterize the effect of changes of dimerization partner on binding to nucleosomal DNA templates. We find that homo- and heterodimeric complexes of these proteins bind to the CACGTG sequence in free DNA with similar affinities. Although Max homodimers bind to nucleosomes, truncated c-Myc homodimers do not. Surprisingly, modifying the c-Myc dimerization interface or changing its dimerization partner to Max enables nucleosomal DNA binding. Thus, changes in dimer structure or dimerization efficiency can have significant effects on nucleosome binding that are not predicted from their affinity for free DNA. We conclude that domains other than the basic region per se influence the ability of a transcription factor to bind to nucleosomal DNA and that changes of dimerization partner can directly affect the ability of a factor to occupy nucleosomal binding sites.
Subject(s)
DNA-Binding Proteins/metabolism , DNA/metabolism , Nucleosomes/metabolism , Proto-Oncogene Proteins c-myc/metabolism , Transcription Factors/metabolism , Base Sequence , Basic-Leucine Zipper Transcription Factors , Binding Sites , Chromatography, Affinity , DNA/isolation & purification , DNA Probes , DNA-Binding Proteins/isolation & purification , Deoxyribonuclease I , Electrophoresis, Polyacrylamide Gel , Kinetics , Macromolecular Substances , Molecular Sequence Data , Oligonucleotide Probes , Proto-Oncogene Proteins c-myc/isolation & purification , Recombinant Fusion Proteins/isolation & purification , Recombinant Fusion Proteins/metabolismABSTRACT
The bmi-1 oncogene cooperates with c-myc in transgenic mice, resulting in accelerated lymphoma development. Altering the expression of Bmi-1 affects normal embryogenesis. The protein product of bmi-1 is homologous to certain Drosophila Polycomb group proteins that regulate homeotic gene expression through alteration of chromatin structure. Chimeric LexA-Bmi-1 protein has previously been shown to repress transcription. How Bmi-1 functions in embryogenesis and whether this relates to the ability of Bmi-1 to mediate cellular transformation is unknown. We demonstrate here that Bmi-1 is able to transform rodent fibroblasts in vitro, providing a system that has allowed us to correlate its molecular properties with its ability to transform cells. We map functional domains of Bmi-1 involved in transcriptional suppression by using the GAL4 chimeric transcriptional regulator system. Deletion analysis shows that the centrally located helix-turn-helix-turn-helix-turn (HTHTHT) motif is necessary for transcriptional suppression whereas the N-terminal RING finger domain is not required. We demonstrate that nuclear localization requires KRMK (residues 230 to 233) and that the absence of nuclear entry ablates transformation. In addition, we find that the subnuclear localization of wild-type Bmi-1 to the rim of the nucleus requires the RING finger domain and correlates with its ability to transform. Our studies with Bmi-1 deletion mutants suggest that the ability of Bmi-1 to mediate cellular transformation correlates with its unique subnuclear localization but not its transcriptional suppression activity.
Subject(s)
Cell Transformation, Neoplastic , Drosophila Proteins , Lymphoma/genetics , Nuclear Proteins/metabolism , Proto-Oncogene Proteins/metabolism , Repressor Proteins , Animals , Antibodies , Cell Line , Cell Nucleus/metabolism , Codon , Drosophila , Embryonic and Fetal Development , Gene Expression Regulation, Developmental , Helix-Turn-Helix Motifs , Mice , Mice, Transgenic , Mutagenesis, Site-Directed , Nuclear Proteins/biosynthesis , Nuclear Proteins/chemistry , Open Reading Frames , Peptide Fragments/chemistry , Peptide Fragments/immunology , Polycomb Repressive Complex 1 , Polymerase Chain Reaction , Proteins/chemistry , Proto-Oncogene Proteins/biosynthesis , Proto-Oncogene Proteins/chemistry , Proto-Oncogene Proteins c-myc/metabolism , Rats , Recombinant Proteins/biosynthesis , Recombinant Proteins/chemistry , Recombinant Proteins/metabolism , Transcription, Genetic , Zinc FingersABSTRACT
Members of the Myc family of proteins share a number of protein motifs that are found in regulators of gene transcription. Conserved stretches of amino acids found in the N-terminal transcriptional activation domain of c-Myc are required for cotransforming activity. Most of the Myc proteins contain the basic helix-loop-helix zipper (bHLH-Zip) DNA-binding motif which is also required for the cotransforming activity of c-Myc. L-Myc, the product of a myc family gene that is highly amplified in many human lung carcinomas, was found to cotransform primary rat embryo cells with an activated ras gene. However, L-Myc cotransforming activity was only 1 to 10% of that of c-Myc (M. J. Birrer, S. Segal, J. S. DeGreve, F. Kaye, E. A. Sausville, and J. D. Minna, Mol. Cell. Biol. 8:2668-2673, 1988). We sought to determine whether functional differences between c-Myc and L-Myc in either the N-terminal or the C-terminal domain could account for the relatively diminished L-Myc cotransforming activity. Although the N-terminal domain of L-Myc could activate transcription when fused to the yeast GAL4 DNA-binding domain, the activity was only 5% of that of a comparable c-Myc domain. We next determined that the interaction of the C-terminal bHLH-Zip region of L-Myc or c-Myc with that of a Myc partner protein, Max, was equivalent in transfected cells. A Max expression vector was found to augment the cotransforming activity of L-Myc as well as that of c-Myc. In addition, a bacterially synthesized DNA-binding domain of L-Myc, like that o c-Myc, heterodimerizes with purified Max protein to bind the core DNA sequence CACGTG. To determine the region of L-Myc responsible for its relatively diminished cotransforming activity, we constructed chimeras containing exons 2 (constituting activation domains) and 3 (constituting DNA-binding domains) of c-Myc fused to those of L-Myc. The cotransforming potencies of these chimeras were compared with those of full-length L-Myc of c-Myc in rat embryo cells. The relative cotransforming activities suggest that the potencies of the activation domains determine the cotransforming efficiencies for c-Myc and L-Myc. This correlation supports the hypothesis that the Myc proteins function in neoplastic cotransformation as transcription factors.